eTable 1. Characteristics of sub-cohort with amyloid PET. Continuous values are presented as the median with the interquartile range. The significance of differences by self-identified race were evaluated with Wilcoxon ranked sum tests for continuous variables and Chi-Square or Fisher exact tests for categorical variables. The covariate-adjusted significance of racial differences was evaluated using ANCOVA models with biomarker concentrations at the outcome measure, race as the predictor variable, and the covariates of age, sex, *APOE* ε4 carrier status, and cognitive status. Plasma p-tau181 and NfL were transformed with the natural logarithm in covariate-adjusted models.

Characteristic	African American Participants n = 49		Non-Hispanic White Participants n = 54		p =	Adjusted p =
Demographics						
Age at CSF collection (years)	68.6 (64.1-73.1)		68.2 (63.5-72.4)		N.S.	
Sex (n, % Female)	30, 61%		28, 52%		N.S.	
APOE ε4 status (n, % carrier)	17, 35%		24, 44%		N.S.	
CDR 0/0.5/1 (% >0)	48/1/0 (2%)		51/2/1 (6%)		N.S.	
Years of education	16 (12-18)		16 (14-18)		N.S.	
Hollingshead index	2.0 (2.0-3.0)		2.0 (1.0-3.0)		0.004	
Hypertension (yes/no/not reported, % yes of reported)	32/17/0 (65%)		18/34/2 (35%)		0.003	
Diabetes (yes/no/not reported, % yes of reported)	12/37/0 (24%)		2/50/2 (4%)		0.004	
CSF/plasma to LP interval (years)	0.11 (0.05-21)		0.08 (0.04-0.23)		N.S.	
CSF biomarker concentrations						
CSF Aβ42 (pg/ml)	49	782 (617-1070)	54	682 (511-860)	0.03	0.04
CSF Aβ40 (pg/ml)	49	9930 (7360-11600)	54	10260 (8990-12200)	N.S.	N.S.
CSF Aβ42/Aβ40	49	0.0879 (0.0819-0.0936)	54	0.0712 (0.0472-0.0865)	<0.0001	0.0001
CSF Aβ42/Aβ40 <0.0673 (n, %)	49	7, 14%	54	25, 46%	0.0005	0.002
CSF total tau (pg/ml)	49	207 (163-270)	54	296 (207-502)	0.0008	0.03
CSF p-tau181 (pg/ml)	49	30.3 (24.0-34.7)	54	38.4 (29.6-55.9)	0.003	0.01
CSF NfL (pg/mL)	46	644 (464-814)	54	728 (537-965)	0.08	N.S.
Plasma biomarker concentrations						
Plasma Aβ42 (pg/ml)	49	43.8 (39.3-49.8)	54	40.2 (37.5-44.8)	0.01	0.007
Plasma Aβ40 (pg/ml)	49	405 (379-469)	54	420 (386-466)	N.S.	N.S.
Plasma Aβ42/Aβ40	49	0.1058 (0.1005-0.1118)	54	0.0962 (0.0903-0.1018)	<0.0001	<0.0001
Plasma p-tau181 (pg/ml)	49	12.2 (10.2-15.1)	54	13.6 (10.0-17.9)	N.S.	N.S.
Plasma p-tau231 (pg/ml)	49	8.3 (4.6-10.6)	54	8.6 (5.6-12.7)	N.S.	N.S.
Plasma NfL (pg/ml)	49	10.5 (7.5-13.5)	54	10.7 (8.8-15.6)	N.S.	N.S.
Amyloid PET						
Centiloid	49	2.3 (-1.0-10.1)	54	10.1 (0.0-33.0)	0.01	0.02
Amyloid PET positive	49	5, 10%	54	21, 39%	0.0008	0.003

eTable 2. Correspondence of plasma biomarkers with CSF Aβ42/Aβ40 or amyloid PET centiloid. The correspondence of plasma biomarker levels with CSF Aβ42/Aβ40 or amyloid PET centiloid was evaluated by either Spearman correlations or partial Spearman correlations that were adjusted for age, sex, *APOE* ε4 carrier status, self-identified race, and cognitive status. 95% confidence intervals are shown in parentheses.

Spearman correlation with CSF Aβ42/Aβ40

	Unadjusted Spearman ρ	*p =*	Adjusted Spearman ρ	*p =*
Plasma Aβ42/Aβ40	0.61 (0.50 to 0.70)	<0.0001	0.52 (0.39 to 0.63)	<0.0001
Plasma p-tau181 (pg/ml)	-0.35 (-0.49 to -0.21)	<0.0001	-0.22 (-0.06 to -0.37)	0.008
Plasma p-tau231 (pg/ml)	-0.29 (-0.43 to -0.14)	0.0003	-0.20 (-0.04 to -0.35)	0.01
Plasma NfL (pg/ml)	-0.22 (-0.37 to -0.07)	0.005	-0.04 (0.12 to -0.20)	N.S.

Spearman correlation with amyloid PET centiloid

	Unadjusted Spearman ρ	*p =*	Adjusted Spearman ρ	*p =*
Plasma Aβ42/Aβ40	-0.44 (-0.58 to -0.27)	<0.0001	-0.30 (-0.10 to -0.47)	0.003
Plasma p-tau181 (pg/ml)	0.32 (0.14 to 0.49)	0.0008	0.22 (0.02 to 0.40)	0.03
Plasma p-tau231 (pg/ml)	0.15 (-0.05 to 0.33)	N.S.	0.09 (-0.11 to 0.29)	N.S.
Plasma NfL (pg/ml)	0.18 (-0.01 to 0.36)	0.07	0.004 (-0.19 to 0.20)	N.S.

eTable 3. Relationship between plasma Aβ42/Aβ40 and CSF Aβ42/Aβ40 or amyloid PET status. Variables included in the model were CSF Aβ42/Aβ40 status (positive < 0.0673), age, self-identified race, sex, *APOE* ε4 carrier status, and cognitive status.

Plasma Aβ42/Aβ40 as a function of CSF Aβ42/Aβ40 status			
Parameter	**Estimate**	**S.E.**	*p =*
Intercept	0.1052	0.0051	<0.0001
CSF Aβ42/Aβ40 status (positive)	-0.008	0.0013	<0.0001
Race (African American)	0.0060	0.0011	<0.0001
Sex (female)	0.0044	0.0011	<0.0001
Age (years)	-0.00010	0.00007	N.S.
APOE ε4 status (carrier)	-0.0009	0.0011	N.S.
Cognitive status (CDR>0)	-0.0010	0.0019	N.S.

Plasma Aβ42/Aβ40 as a function of amyloid PET status			
Parameter	**Estimate**	**S.E.**	*p =*
Intercept	0.0963	0.0069	<0.0001
Amyloid PET status (positive)	-0.0077	0.0018	<0.0001
Race (African American)	0.0068	0.0014	<0.0001
Sex (female)	0.0050	0.0014	0.0005
Age (years)	0.00002	0.0001	N.S.
APOE ε4 status (carrier)	-0.0011	0.0015	N.S.
Cognitive status (CDR>0)	-0.0010	0.0035	N.S.

eTable 4. Relationship between plasma p-tau181 levels and CSF Aβ42/Aβ40 or amyloid PET status. Plasma p-tau181 was transformed with the natural logarithm for analysis. Variables included in the model were CSF Aβ42/Aβ40 status (positive < 0.0673), age, self-identified race, sex, *APOE* ε4 carrier status, and cognitive status.

Ln (plasma p-tau181) as a function of CSF Aβ42/Aβ40 status			
Parameter	Estimate	S.E.	$p =$
Intercept	1.267	0.311	<0.0001
CSF Aβ42/Aβ40 status (positive)	0.239	0.079	0.003
Race (African American)	-0.044	0.066	N.S.
Sex (female)	-0.164	0.065	0.01
Age (years)	0.020	0.004	<0.0001
APOE ε4 status (carrier)	0.017	0.068	N.S.
Cognitive status (CDR>0)	0.278	0.115	0.02

Ln (plasma p-tau181) as a function of amyloid PET status			
Parameter	Estimate	S.E.	$p =$
Intercept	1.277	0.401	0.002
Amyloid PET status (positive)	0.277	0.101	0.008
Race (African American)	-0.0005	0.083	N.S.
Sex (female)	-0.173	0.080	0.03
Age (years)	0.020	0.006	0.0005
APOE ε4 status (carrier)	-0.034	0.088	N.S.
Cognitive status (CDR>0)	0.071	0.205	N.S.

eTable 5. Relationship between plasma p-tau231 levels and CSF Aβ42/Aβ40 or amyloid PET status. Variables included in the model were CSF Aβ42/Aβ40 status (positive < 0.0673), age, self-identified race, sex, *APOE* ε4 carrier status, and cognitive status.

Plasma p-tau231 as a function of CSF Aβ42/Aβ40 status			
Parameter	**Estimate**	**S.E.**	*p =*
Intercept	-1.655	4.474	N.S.
CSF Aβ42/Aβ40 status (positive)	2.525	1.140	0.03
Race (African American)	-0.970	0.946	N.S.
Sex (female)	-0.985	0.940	N.S.
Age (years)	0.160	0.063	0.01
APOE ε4 status (carrier)	-0.190	0.985	N.S.
Cognitive status (CDR>0)	5.585	1.651	0.0009

Plasma p-tau231 as a function of amyloid PET status			
Parameter	**Estimate**	**S.E.**	*p =*
Intercept	2.074	5.300	N.S.
Amyloid PET status (positive)	3.623	1.340	0.008
Race (African American)	0.045	1.090	N.S.
Sex (female)	-1.110	1.061	N.S.
Age (years)	0.105	0.073	N.S.
APOE ε4 status (carrier)	-1.583	1.160	N.S.
Cognitive status (CDR>0)	2.625	2.708	N.S.

eTable 6. Relationship between plasma NfL levels and CSF Aβ42/Aβ40 or amyloid PET status. Plasma NfL was transformed with the natural logarithm for analysis. Variables included in the model were CSF Aβ42/Aβ40 status (positive < 0.0673), age, self-identified race, sex, *APOE* ε4 carrier status, and cognitive status.

Ln (plasma NfL) as a function of CSF Aβ42/Aβ40 status			
Parameter	**Estimate**	**S.E.**	*p =*
Intercept	-0.710	0.357	0.05
CSF Aβ42/Aβ40 status (positive)	-0.015	0.091	N.S.
Race (African American)	-0.091	0.075	N.S.
Sex (female)	-0.052	0.075	N.S.
Age (years)	0.046	0.005	<0.0001
APOE ε4 status (carrier)	0.092	0.079	N.S.
Cognitive status (CDR>0)	0.297	0.132	0.03

Ln (plasma NfL) as a function of amyloid PET status			
Parameter	**Estimate**	**S.E.**	*p =*
Intercept	-1.050	0.432	0.02
Amyloid PET status (positive)	-0.124	0.109	N.S.
Race (African American)	-0.020	0.089	N.S.
Sex (female)	-0.049	0.087	N.S.
Age (years)	0.051	0.006	<0.0001
APOE ε4 status (carrier)	0.130	0.095	N.S.
Cognitive status (CDR>0)	0.209	0.221	N.S.

eTable 7. CSF Aβ42/Aβ40 status or amyloid PET status as predicted by plasma Aβ42/Aβ40 and covariates. Logistic regression models evaluated prediction of CSF Aβ42/Aβ40 (positive < 0.0673) or amyloid PET status by plasma Aβ42/Aβ40 and the covariates of self-identified race, sex, age, *APOE* ε4 carrier status, and cognitive status. For each model, the Receiver Operating Characteristic Area Under the Curve (ROC AUC) with 95% confidence intervals is shown.

CSF Aβ42/Aβ40 status, ROC AUC 0.86 (0.79-0.92)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	18.8	3.3	<0.0001
Plasma Aβ42/Aβ40 (pg/ml)	-197	34	<0.0001

CSF Aβ42/Aβ40 status, ROC AUC 0.90 (0.85-0.96)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	13.0	4.7	0.005
Plasma Aβ42/Aβ40 (pg/ml)	-220	46	<0.0001
Race (African American)	0.058	0.274	N.S.
Sex (female)	0.843	0.568	N.S.
Age (years)	0.109	0.04	0.007
APOE ε4 status (carrier)	0.865	0.269	0.001
Cognitive status (CDR>0)	1.11	0.41	0.007

Amyloid PET status, ROC AUC 0.86 (0.77-0.95)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	18.3	4.2	<0.0001
Plasma Aβ42/Aβ40 (pg/ml)	-198	44	<0.0001

Amyloid PET status, ROC AUC 0.89 (0.82-0.97)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	11.6	5.9	0.05
Plasma Aβ42/Aβ40 (pg/ml)	-223	62.5	0.0004
Race (African American)	-0.025	0.377	N.S.
Sex (female)	0.895	0.739	N.S.
Age (years)	0.123	0.057	0.03
APOE ε4 status (carrier)	0.936	0.378	0.01
Cognitive status (CDR>0)	0.844	0.617	N.S.

eTable 8. CSF Aβ42/Aβ40 status or amyloid PET status as predicted by the amyloid probability score (APS). Logistic regression models evaluated prediction of CSF Aβ42/Aβ40 (positive < 0.0673) or amyloid PET status by the amyloid probability score and the covariates of self-identified race, sex, age, *APOE* ε4 carrier status, and cognitive status. The amyloid probability score is a proprietary modeled value that incorporates plasma Aβ42/Aβ40, age and apolipoprotein E proteotype. For each model, the Receiver Operating Characteristic Area Under the Curve (ROC AUC) with 95% confidence intervals is shown.

CSF Aβ42/Aβ40 status, ROC AUC 0.89 (0.84-0.95)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-2.32	0.33	<0.0001
Amyloid probability score	0.072	0.012	<0.0001

CSF Aβ42/Aβ40 status, ROC AUC 0.91 (0.87-0.96)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-5.15	2.94	0.08
Amyloid probability score	0.075	0.017	<0.0001
Race (African American)	-0.059	0.266	N.S.
Sex (female)	0.74	0.57	N.S.
Age (years)	0.037	0.041	N.S.
APOE ε4 status (carrier)	0.24	0.28	N.S.
Cognitive status (CDR>0)	1.09	0.40	0.007

Amyloid PET status, ROC AUC 0.90 (0.82-0.97)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-2.59	0.42	<0.0001
Amyloid probability score	0.061	0.012	<0.0001

Amyloid PET status, ROC AUC 0.90 (0.84-0.96)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-5.54	3.66	N.S.
Amyloid probability score	0.055	0.016	0.0006
Race (African American)	-0.33	0.35	N.S.
Sex (female)	0.46	0.68	N.S.
Age (years)	0.044	0.051	N.S.
APOE ε4 status (carrier)	0.33	0.37	N.S.
Cognitive status (CDR>0)	0.73	0.65	N.S.

eTable 9. CSF Aβ42/Aβ40 status or amyloid PET status as predicted by plasma p-tau181 levels. Logistic regression models evaluated prediction of CSF Aβ42/Aβ40 (positive < 0.0673) or amyloid PET status by plasma p-tau181 and the covariates of self-identified race, sex, age, *APOE* ε4 carrier status, and cognitive status. Plasma p-tau181 was transformed with the natural logarithm for analysis. For each model, the Receiver Operating Characteristic Area Under the Curve (ROC AUC) with 95% confidence intervals is shown.

CSF Aβ42/Aβ40 status, ROC AUC 0.76 (0.68-0.84)			
Parameter	**Estimate**	**SE**	*p* **=**
Intercept	6.47	1.32	<0.0001
Ln (plasma p-tau181)	-2.14	0.48	<0.0001

CSF Aβ42/Aβ40 status, ROC AUC 0.85 (0.79-0.92)			
Parameter	**Estimate**	**SE**	*p* **=**
Intercept	-8.69	2.71	0.001
Ln (plasma p-tau181)	1.53	0.57	0.007
Race (African American)	-0.59	0.22	0.007
Sex (female)	-0.21	0.44	N.S.
Age (years)	0.072	0.035	0.04
APOE ε4 status (carrier)	0.87	0.23	0.0002
Cognitive status (CDR>0)	1.02	0.39	0.009

Amyloid PET status, ROC AUC 0.74 (0.63-0.84)			
Parameter	**Estimate**	**SE**	*p* **=**
Intercept	-5.99	1.64	0.0003
Ln (plasma p-tau181)	1.84	0.60	0.002

Amyloid PET status, ROC AUC 0.84 (0.75-0.92)			
Parameter	**Estimate**	**SE**	*p* **=**
Intercept	-8.26	3.50	0.02
Ln (plasma p-tau181)	1.78	0.75	0.02
Race (African American)	-0.84	0.31	0.007
Sex (female)	-0.21	0.58	N.S.
Age (years)	0.046	0.044	N.S.
APOE ε4 status (carrier)	0.89	0.31	0.004
Cognitive status (CDR>0)	0.73	0.64	N.S.

eTable 10. CSF Aβ42/Aβ40 status or amyloid PET status as predicted by plasma p-tau231 levels. Logistic regression models evaluated prediction of CSF Aβ42/Aβ40 (positive < 0.0673) or amyloid PET status by plasma p-tau231 and the covariates of self-identified race, sex, age, *APOE* ε4 carrier status, and cognitive status. For each model, the Receiver Operating Characteristic Area Under the Curve (ROC AUC) with 95% confidence intervals is shown.

CSF Aβ42/Aβ40 status, ROC AUC 0.69 (0.60-0.78)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	1.92	0.38	<0.0001
Plasma p-tau231 (pg/ml)	-0.119	0.032	0.0002

CSF Aβ42/Aβ40 status, ROC AUC 0.85 (0.78-0.91)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-6.95	2.50	0.006
Plasma p-tau231 (pg/ml)	0.098	0.040	0.01
Race (African American)	-0.60	0.22	0.006
Sex (female)	-0.37	0.43	N.S.
Age (years)	0.096	0.034	0.004
APOE ε4 status (carrier)	0.94	0.23	<0.0001
Cognitive status (CDR>0)	1.07	0.38	0.006

Amyloid PET status, ROC AUC 0.69 (0.58-0.81)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-2.31	0.52	<0.0001
Plasma p-tau231 (pg/ml)	0.125	0.044	0.004

Amyloid PET status, ROC AUC 0.84 (0.75-0.92)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-6.40	3.26	0.05
Plasma p-tau231 (pg/ml)	0.140	0.055	0.01
Race (African American)	-0.88	0.31	0.005
Sex (female)	-0.39	0.56	N.S.
Age (years)	0.071	0.043	0.10
APOE ε4 status (carrier)	1.00	0.32	0.002
Cognitive status (CDR>0)	0.65	0.61	N.S.

eTable 11. CSF Aβ42/Aβ40 status or amyloid PET status as predicted by plasma NfL levels. Logistic regression models evaluated prediction of CSF Aβ42/Aβ40 (positive < 0.0673) or amyloid PET status by plasma NfL and the covariates of self-identified race, sex, age, *APOE* ε4 carrier status, and cognitive status. Plasma NfL were transformed with the natural logarithm for analysis. For each model, the Receiver Operating Characteristic Area Under the Curve (ROC AUC) with 95% confidence intervals is shown.

CSF Aβ42/Aβ40 status, ROC AUC 0.64 (0.55-0.73)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-2.84	0.83	0.0006
Ln (plasma NfL)	0.85	0.32	0.008

CSF Aβ42/Aβ40 status, ROC AUC 0.81 (0.74-0.89)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-6.20	2.41	0.01
Ln (plasma NfL)	-0.097	0.476	N.S.
Race (African American)	-0.65	0.22	0.003
Sex (female)	-0.50	0.42	N.S.
Age (years)	0.109	0.040	0.007
APOE ε4 status (carrier)	0.89	0.23	<0.0001
Cognitive status (CDR>0)	1.27	0.39	0.001

Amyloid PET status, ROC AUC 0.55 (0.43-0.67)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-1.57	1.02	N.S.
Ln (plasma NfL)	0.199	0.408	N.S.

Amyloid PET status, ROC AUC 0.82 (0.73-0.91)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-6.38	3.28	0.05
Ln (plasma NfL)	-0.87	0.71	N.S.
Race (African American)	-0.89	0.30	0.003
Sex (female)	-0.61	0.54	N.S.
Age (years)	0.131	0.058	0.02
APOE ε4 status (carrier)	0.95	0.31	0.003
Cognitive status (CDR>0)	0.94	0.67	N.S.

eTable 12. CSF Aβ42/Aβ40 status or amyloid PET status as predicted by covariates. Logistic regression models evaluated prediction of CSF Aβ42/Aβ40 (positive < 0.0673) or amyloid PET status by the covariates of self-identified race, sex, age, *APOE* ε4 carrier status, and cognitive status. For each model, the Receiver Operating Characteristic Area Under the Curve (ROC AUC) with 95% confidence intervals is shown.

CSF Aβ42/Aβ40 status, ROC AUC 0.82 (0.74-0.89)			
Parameter	**Estimate**	**SE**	*p* =
Intercept	-6.13	2.39	0.01
Race (African American)	-0.65	0.22	0.003
Sex (female)	-0.50	0.42	N.S.
Age (years)	0.104	0.033	0.001
APOE ε4 status (carrier)	0.88	0.22	<0.0001
Cognitive status (CDR>0)	1.26	0.38	0.0008

Amyloid PET status, ROC AUC 0.81 (0.72-0.90)			
Parameter	**Estimate**	**SE**	*p* =
Intercept	-5.40	3.07	0.08
Race (African American)	-0.86	0.30	0.004
Sex (female)	-0.60	0.53	N.S.
Age (years)	0.084	0.042	0.04
APOE ε4 status (carrier)	0.86	0.29	0.003
Cognitive status (CDR>0)	0.81	0.63	N.S.

eTable 13. CSF Aβ42/Aβ40 status as predicted by plasma biomarkers and covariates in only cognitively normal individuals. Logistic regression models evaluated prediction of CSF Aβ42/Aβ40 status (positive < 0.0673) by each plasma biomarker and the covariates of self-identified race, sex, age, and *APOE* ε4 carrier status in only cognitively normal individuals. Plasma p-tau181 and NfL were transformed with the natural logarithm for analysis. For each model, the Receiver Operating Characteristic Area Under the Curve (ROC AUC) with 95% confidence intervals is shown.

Plasma Aβ42/Aβ40, ROC AUC 0.89 (0.83-0.95)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	9.7	4.7	0.04
Plasma Aβ42/Aβ40 (pg/ml)	-205	46	<0.0001
Race (African American)	0.049	0.29	N.S.
Sex (female)	0.961	0.598	N.S.
Age (years)	0.118	0.041	0.004
APOE ε4 status (carrier)	0.92	0.28	0.001

Plasma p-tau181, ROC AUC 0.84 (0.77-0.92)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-10.34	2.86	0.0003
Ln (plasma p-tau181)	1.57	0.60	0.009
Race (African American)	-0.56	0.23	0.02
Sex (female)	-0.10	0.47	N.S.
Age (years)	0.077	0.036	0.03
APOE ε4 status (carrier)	0.93	0.24	0.0001

Plasma p-tau231, ROC AUC 0.84 (0.77-0.91)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-8.82	2.69	0.001
Plasma p-tau231 (pg/ml)	0.12	0.043	0.007
Race (African American)	-0.57	0.24	0.02
Sex (female)	-0.23	0.46	N.S.
Age (years)	0.10	0.03	0.003
APOE ε4 status (carrier)	1.00	0.25	<0.0001

Plasma NfL, ROC AUC 0.80 (0.72-0.88)			
Parameter	**Estimate**	**SE**	*p =*
Intercept	-8.00	2.61	0.002
Ln (plasma NfL)	-0.054	0.504	N.S.
Race (African American)	-0.63	0.23	0.006
Sex (female)	-0.39	0.44	N.S.
Age (years)	0.11	0.042	0.008
APOE ε4 status (carrier)	0.94	0.24	<0.0001

eTable 14. CSF Aβ42/Aβ40 status or amyloid PET status as predicted by plasma Aβ42/Aβ40, p-tau181, p-tau231 and NfL levels with covariates. Logistic regression models evaluated prediction of CSF Aβ42/Aβ40 (positive < 0.0673) or amyloid PET status by Aβ42/Aβ40, p-tau181, p-tau231 and NfL levels and the covariates of self-identified race, sex, age, *APOE* ε4 carrier status and cognitive status. Plasma p-tau181 and plasma NfL were transformed with the natural logarithm for analysis. For each model, the Receiver Operating Characteristic Area Under the Curve (ROC AUC) with 95% confidence intervals is shown.

CSF Aβ42/Aβ40 status, ROC AUC 0.92 (0.88-0.96)			
Parameter	**Estimate**	**SE**	***p =***
Intercept	8.78	5.19	0.09
Plasma Aβ42/Aβ40 (pg/ml)	-204	45	<0.0001
Ln (plasma p-tau181)	1.03	1.12	N.S.
Plasma p-tau231 (pg/ml)	0.06	0.07	N.S.
Ln (plasma NfL)	-0.82	0.63	N.S.
Race (African American)	0.007	0.28	N.S.
Sex (female)	1.10	0.62	0.08
Age (years)	0.12	0.05	0.01
APOE ε4 status (carrier)	0.89	0.28	0.002
Cognitive status (CDR>0)	0.92	0.44	0.03

Amyloid PET status, ROC AUC 0.93 (0.89-0.98)			
Parameter	**Estimate**	**SE**	***p =***
Intercept	1.33	6.4	N.S.
Plasma Aβ42/Aβ40 (pg/ml)	-212	60	0.0004
Ln (plasma p-tau181)	2.51	1.56	N.S.
Plasma p-tau231 (pg/ml)	0.06	0.11	N.S.
Ln (plasma NfL)	-2.88	1.07	0.007
Race (African American)	-0.10	0.40	N.S.
Sex (female)	1.64	0.94	0.08
Age (years)	0.24	0.09	0.007
APOE ε4 status (carrier)	1.25	0.46	0.006
Cognitive status (CDR>0)	0.99	0.70	N.S.

eFig. 1. Relationship of plasma p-tau231 with CSF Aβ42/Aβ40 and amyloid PET. Plasma p-tau231 was transformed with the natural logarithm for analysis. The relationship between plasma p-tau231 and CSF Aβ42/Aβ40 (**A**) or amyloid PET centiloid (**C**) was evaluated by partial Spearman correlation and was adjusted for age, sex, *APOE* ε4 carrier status, self-identified race and cognitive status. Vertical dotted lines represent cut-off values for amyloid positivity. Plasma p-tau231 levels for AA and NHW groups were evaluated by CSF Aβ42/Aβ40 status (positive < 0.0673) (**B**) or amyloid PET status (**D**). Cut-off values for plasma p-tau231 with the highest combined sensitivity and specificity for distinguishing amyloid status were selected and are denoted by horizontal dashed lines. The Receiver Operating Characteristic Area Under the Curve (ROC AUC), positive percent agreement (PPA) and negative percent agreement (NPA) are shown. Point types denote the following: 1) race: red, AA; black, NHW; 2) cognitive status: open circle, CDR 0; closed square, CDR>0.

eFig. 2. Relationship of plasma NfL with CSF Aβ42/Aβ40 and amyloid PET.
Plasma NfL was transformed with the natural logarithm for analysis. The relationship between plasma NfL and CSF Aβ42/Aβ40 (**A**) or amyloid PET centiloid (**C**) was evaluated by partial Spearman correlation and was adjusted for age, sex, *APOE* ε4 carrier status, self-identified race, and cognitive status. Vertical dotted lines represent cut-off values for amyloid positivity. Plasma NfL levels for AA and NHW groups were evaluated by CSF Aβ42/Aβ40 status (positive < 0.0673) (**B**) or amyloid PET status (**D**). Cut-off values for plasma NfL with the highest combined sensitivity and specificity for distinguishing amyloid status were selected and are denoted by horizontal dashed lines. The Receiver Operating Characteristic Area Under the Curve (ROC AUC), positive percent agreement (PPA) and negative percent agreement (NPA) are shown. Point types denote the following: 1) race: red, AA; black, NHW; 2) cognitive status: open circle, CDR 0; closed square, CDR>0.